Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science

Author:

Ding Linda,Bradford Carla,Kuo I-Lin,Fan Yankhua,Ulin Kenneth,Khalifeh Abdulnasser,Yu Suhong,Liu Fenghong,Saleeby Jonathan,Bushe Harry,Smith Koren,Bianciu Camelia,LaRosa Salvatore,Prior Fred,Saltz Joel,Sharma Ashish,Smyczynski Mark,Bishop-Jodoin Maryann,Laurie Fran,Iandoli Matthew,Moni Janaki,Cicchetti M. Giulia,FitzGerald Thomas J.

Abstract

The future of radiation oncology is exceptionally strong as we are increasingly involved in nearly all oncology disease sites due to extraordinary advances in radiation oncology treatment management platforms and improvements in treatment execution. Due to our technology and consistent accuracy, compressed radiation oncology treatment strategies are becoming more commonplace secondary to our ability to successfully treat tumor targets with increased normal tissue avoidance. In many disease sites including the central nervous system, pulmonary parenchyma, liver, and other areas, our service is redefining the standards of care. Targeting of disease has improved due to advances in tumor imaging and application of integrated imaging datasets into sophisticated planning systems which can optimize volume driven plans created by talented personnel. Treatment times have significantly decreased due to volume driven arc therapy and positioning is secured by real time imaging and optical tracking. Normal tissue exclusion has permitted compressed treatment schedules making treatment more convenient for the patient. These changes require additional study to further optimize care. Because data exchange worldwide have evolved through digital platforms and prisms, images and radiation datasets worldwide can be shared/reviewed on a same day basis using established de-identification and anonymization methods. Data storage post-trial completion can co-exist with digital pathomic and radiomic information in a single database coupled with patient specific outcome information and serve to move our translational science forward with nimble query elements and artificial intelligence to ask better questions of the data we collect and collate. This will be important moving forward to validate our process improvements at an enterprise level and support our science. We have to be thorough and complete in our data acquisition processes, however if we remain disciplined in our data management plan, our field can grow further and become more successful generating new standards of care from validated datasets.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference50 articles.

1. Treatment Volume and Tissue Tolerance;Withers;Int J Radiat Oncol Biol Phys,1988

2. Tolerance of Normal Tissue to Therapeutic Irradiation;Emami;Int J Radiat Oncol Biol Phys,1991

3. A Unified Model of Tissue Response to Radiation;Niemierko;Med Phys,1999

4. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues;Bentzen;Int J Radiat Oncol Biol Phys,2010

5. Use of Normal Tissue Complication Probability Models in the Clinic;Marks;Int J Radiat Oncol Biol Phys,2010

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3